Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey
Jeff Richardson (),
Gang Chen () and
Additional contact information
Jeff Richardson: Monash Business School, Monash University
Angelo Iezzi: Monash Business School, Monash University
Aimee Maxwell: Monash Business School, Monash University
PharmacoEconomics - Open, 2017, vol. 1, issue 1, 13-23
Abstract Introduction This paper suggests and tests a reason why the public might support the funding of services for rare diseases (SRDs) when the services are effective but not cost effective, i.e. when more health could be produced by allocating funds to other services. It is postulated that the fairness of funding a service is influenced by a comparison of the average patient benefit with the average cost to those who share the cost. Methods Survey respondents were asked to allocate a budget between cost-effective services that had a small effect upon a large number of relatively well patients and SRDs that benefited a small number of severely ill patients but were not cost effective because of their high cost. Results Part of the budget was always allocated to the SRDs. The budget share rose with the number sharing the cost. Discussion Sharing per se appears to characterise preferences. This has been obscured in studies that focus upon cost per patient rather than cost per person sharing the cost.
References: View references in EconPapers View complete reference list from CitEc
Citations Track citations by RSS feed
Downloads: (external link)
http://link.springer.com/10.1007/s41669-016-0002-3 Abstract (text/html)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:1:y:2017:i:1:d:10.1007_s41669-016-0002-3
Ordering information: This journal article can be ordered from
Access Statistics for this article
PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell
More articles in PharmacoEconomics - Open from Springer
Series data maintained by Sonal Shukla ().